CriticalCentrally acting cough suppressant×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B)
Updated · Methodology
Mechanism
Phenelzine is a potent monoamine oxidase (MAO) inhibitor (phenelzine label, US Food and Drug Administration, FDA, Description). Dextromethorphan has mild serotonergic properties (dextromethorphan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Serious reactions resembling serotonin syndrome have occurred when dextromethorphan was combined with MAO inhibitors. The Spanish dextromethorphan SmPCs say they may be linked to its serotonergic properties and to inhibition of its hepatic metabolism (dextromethorphan SmPC, AEMPS, section 4.5).
Symptoms
The Spanish dextromethorphan summaries of product characteristics (SmPCs) describe the serious reactions with monoamine oxidase (MAO) inhibitors as serotonin syndrome: neuromuscular hyperactivity (tremor, clonus, myoclonus, hyperreflexia, pyramidal rigidity), autonomic hyperactivity (sweating, fever, fast heart rate, fast breathing, dilated pupils) and mental status changes (agitation, excitement, confusion) (dextromethorphan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Another Spanish dextromethorphan SmPC also lists nausea, coma, low or high blood pressure, leg tremor, muscle spasms and very high fever, which could lead to myocardial infarction and death (dextromethorphan SmPC, AEMPS, section 4.5). According to the US phenelzine label, dextromethorphan may cause reactions similar to those seen with pethidine (meperidine) in patients on MAO inhibitors (excitation, seizures, delirium, hyperpyrexia, circulatory collapse, coma, death). Drowsiness and bizarre behaviour have been reported in a patient taking phenelzine after a dextromethorphan lozenge (phenelzine label, US Food and Drug Administration, FDA, Contraindications and Warnings).
Management
The combination is contraindicated. The Spanish dextromethorphan summaries of product characteristics (SmPCs) contraindicate dextromethorphan during treatment with monoamine oxidase (MAO) inhibitors, including antidepressants of this class, and for 2 weeks afterwards (dextromethorphan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.3). The US phenelzine label explicitly contraindicates combining phenelzine with dextromethorphan (phenelzine label, US Food and Drug Administration, FDA, Contraindications). Phenelzine is not authorised in Spain, so information on it comes from the US label. Dextromethorphan is sold in Spain without a prescription, including in multi-ingredient products (AEMPS medicines register). The US phenelzine label lists cold and cough preparations containing dextromethorphan among the over-the-counter medicines to avoid during phenelzine treatment and for two weeks after stopping it (FDA phenelzine label, Warnings). Start dextromethorphan no earlier than 14 days after stopping phenelzine (dextromethorphan SmPC, AEMPS, sections 4.3 and 4.5; FDA over-the-counter dextromethorphan label, Warnings). Before starting phenelzine after a serotonergic agent, allow enough time for the agent and its active metabolites to clear from the body (FDA phenelzine label, Contraindications). Dextromethorphan has mild serotonergic properties (dextromethorphan SmPC, AEMPS, section 5.1). If serotonin syndrome is suspected, stop dextromethorphan (dextromethorphan SmPC, AEMPS, section 4.4). Benzodiazepines can be used for seizures. For hyperthermia caused by serotonin syndrome, use benzodiazepines together with external cooling (dextromethorphan SmPC, AEMPS, section 4.9).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Nardil (phenelzine sulfate tablets, USP) – prescribing information (2025)– FDA label, Parke-Davis Div of Pfizer, DailyMed setid 513a41d0-37d4-4355-8a6d-a2c643bce6fa, version 11, 06/2025, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Dextrometorfano (nº registro 70997), sección 4.3 (2026)– AEMPS, CIMA, nº registro 70997 (Laitos 3 mg/ml jarabe), revisión 08/2026, sección 4.3
- AEMPS: Ficha técnica: Dextrometorfano, Cinfatos Antitusivo Flas 15 mg comprimidos bucodispersables (nº registro 85817), sección 4.5 (2025)– AEMPS, CIMA, nº registro 85817, revisión 12/2025, secciones 4.3 y 4.5
- FDA: Delsym Cough (dextromethorphan) OTC Drug Facts label (2026)– FDA, DailyMed, Reckitt Benckiser, setid a43d59f9-3a6c-4a7c-b98d-b86d6035f716, revised 05/2026, Drug Facts: Warnings
- AEMPS: Ficha técnica: Dextrometorfano, Bisolvon Antitusivo 2 mg/ml jarabe (nº registro 57174), sección 4.3 (2026)– AEMPS, CIMA, nº registro 57174 (Opella Healthcare Spain), revisión 01/2026, secciones 4.3, 4.4, 4.5, 4.9 y 5.1